AntlerA Therapeutics

10:30 AM - 10:45 AM (PDT), Thursday, June 16, 2022
A regenerative medicine-focused preclinical-stage company developing novel antibody therapeutics for precise Wnt signaling modulation
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Regenerative Medicine
Lead Product in Development:
inflammatory bowel disease (IBD) molecule
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided